Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients
Pelttari, Liisa M; Nurminen, Riikka; Gylfe, Alexsandra; Aaltonen, Lauri; Schleutker, Johanna; Nevanlinna, Heli (2012)
2012
BMC Cancer 12
552
Biolääketieteellisen teknologian yksikkö - Institute of Biomedical Technology
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited.
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:uta-201301041003
https://urn.fi/URN:NBN:fi:uta-201301041003
Kuvaus
BioMed Central open access
Tiivistelmä
Background
Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. Risk for other cancers has not been studied.
Methods
To study the role of RAD51C mutations in other common cancer types, we genotyped the Finnish RAD51C founder mutations c.837 + 1G > A and c.93delG in 1083 prostate cancer patients and 802 colorectal cancer patients using TaqMan Real-Time PCR.
Results
No RAD51C mutations c.837 + 1G > A or c.93delG were detected among the prostate or colorectal cancer patients.
Conclusions
The results suggest that the RAD51C mutations do not predispose to prostate or colorectal cancer.
Keywords:
RAD51C; Prostate cancer; Colorectal cancer; Breast cancer; Ovarian cancer; Founder mutation
Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. Risk for other cancers has not been studied.
Methods
To study the role of RAD51C mutations in other common cancer types, we genotyped the Finnish RAD51C founder mutations c.837 + 1G > A and c.93delG in 1083 prostate cancer patients and 802 colorectal cancer patients using TaqMan Real-Time PCR.
Results
No RAD51C mutations c.837 + 1G > A or c.93delG were detected among the prostate or colorectal cancer patients.
Conclusions
The results suggest that the RAD51C mutations do not predispose to prostate or colorectal cancer.
Keywords:
RAD51C; Prostate cancer; Colorectal cancer; Breast cancer; Ovarian cancer; Founder mutation
Kokoelmat
- Artikkelit [6122]